NATALEE leads breast cancer buzz as ESMO 2026 draws packed sessions
Start here
At the European Society for Medical Oncology congress on October 23, 2026, attention across the breast cancer track clustered around a handful of trials. NATALEE drew the most mentions with 28, followed by trials labeled HER2 with 22 and KEYNOTE-866 with 21. Rounding out the most-cited list were TALENT (17), PANKU-BREAST01 (16), KEYNOTE-B15 (13), nivolumab (13) and HORIZON-BREAST06 (12). The picture comes from a floor digest of conversation and coverage at the meeting. What has not yet emerged from this snapshot is any detail on the results themselves, which trials moved practice discussion forward, or how clinicians are weighing the newer entrants against established regimens.
Written by a model from the reports
Coverage timeline
Follow the coverage to see the different angles.
- cba-usa.newsESMO 2026 · 10 2026-10-23 floor digest
1. NATALEE (28); 2. HER2 (22); 3. KEYNOTE-866 (21); 4. TALENT (17); 5. PANKU-BREAST01 (16); 6. KEYNOTE-B15 (13); 7. nivolumab (13); 8. HORIZON-BREAST06 (12)
Heat trend for this story
Heat now 1·Peak in the comparable set 10 (Oct 24 12:00)·Change over 24h in the comparable set -50%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.